DEF: Nurix Therapeutics Advances Key Programs, Strengthens Balance Sheet

Nurix Therapeutics reports significant progress in its oncology and inflammation & immunology pipelines, highlighted by pivotal trial advancements for bexobrutideg and a strengthened financial position.

Summary

• Bexobrutideg (BTK degrader) advanced into registrational development for relapsed/refractory chronic lymphocytic leukemia (CLL).
• Phase 1a/1b data for bexobrutideg in heavily pretreated CLL patients showed an 83.0% objective response rate (ORR), including two complete responses, with a median progression-free survival (PFS) of 22.1 months and median duration of response (DOR) of 20.1 months.
• The 600 mg dose of bexobrutideg was selected as the recommended Phase 2 dose, aligning with FDA's Project Optimus.
• Bexobrutideg demonstrated a consistent safety profile with no dose-limiting toxicities, systemic fungal infections, or Grade 4 infections.
• Encouraging Phase 1 data for bexobrutideg in Waldenström macroglobulinemia (WM) showed a 75.0% ORR, with median DOR and PFS not yet reached.
• Zelebrudomide (dual BTK and cereblon neosubstrate degrader) progressed through dose escalation with a new chirally controlled drug form.
• NX-1607 (oral CBL-B inhibitor) generated monotherapy signals of efficacy with a disease control rate of 49.3% across doses and tumor types.
• The DAYBreak-201 Phase 2 study in relapsed/refractory CLL is designed as a pivotal trial to support accelerated approval in the United States.
• Plans were announced for DAYBreak-306, a Phase 3 trial that will test bexobrutideg head-to-head against pirtobrutinib, aiming for full approval and practice-changing data.
• Sanofi exercised its option to extend its license for the STAT6 program, including development candidate NX-3911, which is in investigational new drug (IND) enabling studies.
• GS-6791 (IRAK4 degrader, with Gilead) demonstrated potent and sustained IRAK4 degradation and meaningful efficacy in an animal model of atopic dermatitis, and began a first-in-human Phase 1 study in healthy volunteers.
• Ended fiscal 2025 with $592.9 million in cash, cash equivalents, and marketable securities.
• Completed a $250.0 million underwritten registered offering in October 2025 with participation from leading healthcare-focused institutional investors.
• Recognized $84.0 million in revenue from collaborations with Gilead, Sanofi, and Pfizer in 2025.
• Remains eligible for up to $6.1 billion in future fees and milestones, plus royalties on product sales from partnerships.
• The Degrader Antibody Conjugate (DAC) collaboration with Pfizer achieved multiple preclinical milestones.
• 2026 priorities include advancing bexobrutideg to Phase 3, expanding its clinical program to include selected inflammation and immunology (I&I) indications, supporting partner programs (STAT6, IRAK4), and defining expansion paths for zelebrudomide and NX-1607.
• The company believes it is approaching an inflection point in its efforts to develop innovative, targeted protein degradation drugs to treat serious disease.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing as highly positive, reflecting strong clinical data for its lead asset, significant pipeline advancements, robust financial health, and strategic execution on partnerships, positioning the company for substantial future growth.

Positives

• Bexobrutideg's strong Phase 1a/1b data in heavily pretreated CLL patients showed an 83.0% objective response rate (ORR), including two complete responses, with a median progression-free survival (PFS) of 22.1 months and median duration of response (DOR) of 20.1 months.
• Bexobrutideg demonstrated a favorable safety profile with no dose-limiting toxicities, no systemic fungal infections, and no Grade 4 infections.
• Initiation of the DAYBreak-201 Phase 2 pivotal trial for accelerated approval in the U.S. for relapsed/refractory CLL.
• Plans for DAYBreak-306, a Phase 3 trial, to compare bexobrutideg head-to-head against pirtobrutinib, aiming for full approval and practice-changing data.
• Encouraging Phase 1 data for bexobrutideg in Waldenström macroglobulinemia (WM) with a 75.0% ORR and median DOR/PFS not yet reached.
• Advancement of other oncology pipeline candidates, including Zelebrudomide and NX-1607, which showed a 49.3% disease control rate in solid tumors.
• Sanofi extended its license for the STAT6 program, with NX-3911 progressing into IND-enabling studies.
• Gilead's IRAK4 degrader (GS-6791) entered a first-in-human Phase 1 clinical study, supported by strong preclinical data.
• Strong financial position with $592.9 million in cash, cash equivalents, and marketable securities at fiscal year-end 2025.
• Successful completion of a $250.0 million underwritten equity offering in October 2025, strengthening the balance sheet.
• Generated significant collaboration revenue of $84.0 million in 2025 and remains eligible for up to $6.1 billion in future milestones and royalties.
• The Pfizer Degrader Antibody Conjugate (DAC) collaboration achieved multiple preclinical milestones, validating the DEL-AI platform.
• Maintains valuable option rights to co-develop and co-commercialize products in the U.S. with partners.
• Enhanced executive leadership team and Board of Directors with commercial and development expertise to support late-stage development.

Risks

• Uncertainty regarding the ability to advance drug candidates, obtain regulatory approval, and ultimately commercialize them.
• Uncertainties related to the timing and results of preclinical studies and clinical trials.
• Whether Nurix will be able to fund development activities and achieve development goals.
• Uncertainties related to the timing and receipt of payments from collaboration partners, including milestone payments and royalties on future product sales.
• The potential impact of global business, political, and macroeconomic conditions, cybersecurity events, instability in the banking system, and global events, including regional conflicts, on Nurix's business, clinical trials, financial condition, liquidity, and results of operations.
• Whether Nurix will be able to protect its intellectual property.
• Other risks and uncertainties described under the heading 'Risk Factors' in Nurix's Annual Report on Form 10-K for the year ended November 30, 2025, and other Securities and Exchange Commission filings.

Future Outlook

Nurix Therapeutics plans to advance bexobrutideg to Phase 3 and broaden its clinical program to include selected inflammation and immunology (I&I) indications in 2026. The company will also support the advancement of Sanofi's STAT6 degrader and Gilead's IRAK4 degrader through IND-enabling and early clinical evaluation, and define expansion paths for zelebrudomide and NX-1607 in high-value oncology indications. The company expects 2026 to be a significant year as clinical trials progress towards delivering new therapies.

Management Comments

• "As we reflect on 2025 and look ahead to 2026 and beyond, Nurix enters its next chapter with a pivotal development program in chronic lymphocytic leukemia (CLL) underway."
• "Our focus remains clear: to establish degrader-based medicines at the forefront of patient care in oncology and autoimmune disease."
• "Collectively, these results position bexobrutideg as a potentially transformative once-daily, oral therapy for patients with B-cell malignancies."
• "We believe this profile [of bexobrutideg] may offer a more effective and safe therapeutic option for chronic autoimmune diseases where sustained control of pathogenic B-cell and myeloid signaling must be balanced with long-term tolerability."
• "We believe we are approaching an inflection point in our efforts to develop innovative, targeted protein degradation drugs to treat serious disease."
• "We expect 2026 will be a significant year for Nurix as we progress our clinical trials with the ultimate goal of delivering new therapies for patients in need."

Industry Context

StockSavvy.ai notes that Nurix's focus on targeted protein degradation (TPD) with its DEL-AI platform positions it at the forefront of a rapidly evolving area in drug discovery, offering a differentiated approach compared to traditional kinase inhibitors. The head-to-head Phase 3 trial of bexobrutideg against pirtobrutinib (a non-covalent BTK inhibitor) is a bold move that could establish TPD as superior to mere enzymatic inhibition, potentially setting new standards in B-cell malignancies. The expansion into inflammation and immunology (I&I) with STAT6 and IRAK4 degraders aligns with a broader industry trend of leveraging oncology-proven mechanisms for autoimmune diseases, seeking to address limitations of existing antibody or inhibitor strategies.

Comparison to Industry Standards

• Bexobrutideg's 83.0% ORR in heavily pretreated CLL patients, with a median PFS of 22.1 months and DOR of 20.1 months, appears competitive, especially given the patient population has progressed after all approved agents, including covalent and non-covalent BTK inhibitors. This compares favorably to the efficacy seen with other BTK inhibitors in similar refractory settings, such as pirtobrutinib which has shown high ORRs but often in less heavily pretreated populations or with shorter follow-up.
• The planned head-to-head Phase 3 trial (DAYBreak-306) against pirtobrutinib is a direct challenge to a leading non-covalent BTK inhibitor, aiming to demonstrate superior efficacy by degrading the BTK protein rather than just inhibiting its function. This could differentiate bexobrutideg significantly from competitors like Eli Lilly's Jaypirca (pirtobrutinib) or AstraZeneca's Calquence (acalabrutinib) and AbbVie/Johnson & Johnson's Imbruvica (ibrutinib).
• The 75.0% ORR in Waldenström macroglobulinemia (WM) with median DOR and PFS not reached suggests a durable response, which is a strong indicator in a disease where long-term control is crucial. This is comparable to or potentially better than existing BTK inhibitors in WM, such as ibrutinib or acalabrutinib, which have demonstrated high response rates but with established median PFS/DOR.
• The disease control rate of 49.3% for NX-1607 (CBL-B inhibitor) in solid tumors indicates early signs of efficacy, which is a promising start for a first-in-class mechanism in a challenging area like solid tumors, where many immunotherapies struggle.

Management Changes

Corporate Governance

Related Party Transactions

• From December 1, 2024, to the present, there have been no transactions, and there are currently no proposed transactions, in which the amount involved exceeded $120,000 and in which Nurix or any of its subsidiaries was (or is to be) a party and in which any director, director nominee, executive officer, holder of more than 5% of Nurix's capital stock, or any immediate family member of or person sharing the household with any of these individuals, had (or will have) a direct or indirect material interest, except for payments set forth under Proposal No. 1 Election of Class III Directors and Executive Compensation.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through pipeline advancements, strong clinical data, strategic partnerships, and a strengthened balance sheet. The $250M equity offering is dilutive but strengthens financial position for accelerated program execution.
• Employees: Commitment to fair treatment, competitive compensation, professional growth, equality, and respect. Employee development and training emphasized.
• Patients: Development of potentially transformative once-daily, oral therapies for B-cell malignancies (CLL, WM) and autoimmune diseases, aiming for more effective and safer options.
• Partners (Gilead, Sanofi, Pfizer): Continued validation of the DEL-AI platform and progress in collaborative programs, indicating successful and productive relationships.
• Regulatory Authorities: Adherence to FDA's Project Optimus and plans for registrational trials.

Next Steps

• Execute the DAYBreak-201 and DAYBreak-306 studies towards registration for CLL in multiple major markets.
• Complete the new tablet formulation SAD/MAD study for bexobrutideg in I&I and file an IND in a selected I&I indication.
• Support advancement of Sanofi's STAT6 degrader and Gilead's IRAK4 degrader through IND-enabling and early clinical evaluation.
• Define expansion paths for zelebrudomide and NX-1607 in high-value oncology indications.
• Continue advancing DEL-AI derived programs, including DACs with Pfizer, toward development candidate selection.
• Hold the 2026 Annual Meeting of Stockholders on May 15, 2026.
• Elect three Class III directors at the Annual Meeting.
• Ratify the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending November 30, 2026.
• Approve, on a non-binding advisory basis, the compensation of named executive officers.

Key Dates

Recommendation

The filing highlights exceptional clinical data for bexobrutideg in a challenging patient population (83% ORR, 22.1 months PFS in heavily pretreated CLL), positioning it as a potential best-in-class therapy. The initiation of pivotal trials and a head-to-head Phase 3 study against a leading competitor demonstrates strong confidence and a clear path to market. Furthermore, the robust financial position, significant collaboration revenue, and substantial potential future milestones underscore the company's strategic execution and long-term value creation potential. The expansion into I&I also broadens the market opportunity.

Keywords

Nurix Therapeutics, oncology, chronic lymphocytic leukemia, CLL, Bruton's tyrosine kinase, BTK degrader, bexobrutideg, Waldenström macroglobulinemia, WM, protein degradation, inflammation and immunology, I&I, STAT6, IRAK4, Sanofi, Gilead, Pfizer, DEL-AI platform, drug development, clinical trials, Phase 1, Phase 2, Phase 3, accelerated approval, pirtobrutinib, zelebrudomide, NX-1607, CBL-B inhibitor, NX-3911, GS-6791, atopic dermatitis, Degrader Antibody Conjugate, DAC, financial results, cash, equity offering, collaboration revenue, milestones, royalties, corporate governance, executive compensation